Abstract
Genetic profiling of non-small cell lung cancer (NSCLC) tissue has identified alterations in a number of genes, including c-MET. Dysregulation of c-MET, a receptor tyrosine kinase mesenchymal epithelial transition factor, is associated with worse prognosis. Therapeutics targeting c-MET such as the antibody drug conjugate (ADC) Telisotuzimab vedotin (Teliso-V) may be of benefit. Currently, immunohistochemical staining of tissue is used to determine whether c-MET protein is overexpressed. Here we report development of a machine learning (ML)-powered method that identifies features of the tumor microenvironment (TME) as predictors of c-MET overexpression status (positive vs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
